Details of the Drug

General Information of Drug (ID: DMIJGT9)

Drug Name
INCB24360
Synonyms Epacadostat
Indication
Disease Entry ICD 11 Status REF
Urothelial carcinoma 2C92.0 Phase 3 [1]
Melanoma 2C30 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
B-cell lymphoma 2A86 Phase 1 [2]
Colorectal cancer 2B91.Z Phase 1 [2]
Head and neck cancer 2D42 Phase 1 [2]
Lung cancer 2C25.0 Phase 1 [2]
Lymphoma 2A80-2A86 Phase 1 [2]
Merkel cell carcinoma 2C34 Phase 1 [2]
Ovarian cancer 2C73 Phase 1 [2]
Recurrent glioblastoma 2A00.00 Phase 1 [4]
⏷ Show the Full List of Indication(s)
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 438.24
Logarithm of the Partition Coefficient (xlogp) 0.8
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 11
Chemical Identifiers
Formula
C11H13BrFN7O4S
IUPAC Name
N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide
Canonical SMILES
C1=CC(=C(C=C1N=C(C2=NON=C2NCCNS(=O)(=O)N)NO)Br)F
InChI
InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)
InChIKey
FBKMWOJEPMPVTQ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
135564890
CAS Number
1204669-58-8
TTD ID
D0G7MV
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Indoleamine 2,3-dioxygenase 1 (IDO1) TTZJYKH I23O1_HUMAN Inhibitor [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Indoleamine 2,3-dioxygenase 1 (IDO1) OT91DBN7 I23O1_HUMAN Gene/Protein Processing [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03361865) Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8221).
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Incyte. Product Development Pipeline.
6 Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells. Toxicol Appl Pharmacol. 2020 Oct 1;404:115203. doi: 10.1016/j.taap.2020.115203. Epub 2020 Aug 19.